Table 1. Dose fractionation, late genitourinary (GU) and gastrointestinal (GI) toxicity, and biochemical disease-free survival by risk groups in HDR boost series.
| Author | N | Dose (Gy)/fractions + EBRT | Median FU (yrs) | Late G3 toxicity (%) | Biochemical DFS (%) | ||||
|---|---|---|---|---|---|---|---|---|---|
| GU | GI | Low | Intermediate | High | |||||
| Agoston (16) | 100 | 10/1+60/30 | 5.2 | 14 | 2 | 84 | 82 | ||
| Aluwini (17) | 264 | 18/3+45/25 | 6.25 | 4 | 1 | 97 | – | – | |
| Bachand (18) | 153 | 18-20/2+44/22 | 3.7 | – | – | – | 96 | – | |
| Cury (19) | 121 | 10/1+50/20 | 5.25 | 2 | 2 | – | 91 | – | |
| Deutsch (20) | 160 | 21/3+50.4/28 | 4.4 | 100 | 98 | 93 | |||
| Galalae (21) | 122 | 30/2+50/25 | 9.8 | 5 | 3 | 74 | 64 | 67 | |
| Helou (22)/Shahid (23) | 60 | 20/2+45/25 | 8.3 | 3 | 0 | – | 93 | – | |
| 123 | 15/1+37.5/15 | 6.2 | 4 | 0 | 97 | ||||
| Joseph (24) | 95 | 12.5/1+37.5/15 | 5.4 | – | – | – | 82 | 78 | |
| Kaprealian (25) | 64 | 18/3+45/25 | 8.8 | 1 | 0 | – | 84 | 80 | |
| 101 | 19/2+45/25 | 3.6 | – | 94 | 82 | ||||
| Khor (26) | 344 | 19.5/3+46/23 | 5.1 | 2 | 0 | – | 84 | 74 | |
| Kotecha (27) | 229 | 16.5–22.5/3+50.4/28 | 5.1 | 5 | 0.4 | – | – | – | |
| Lilleby (28) | 275 | 20/2+50/25 | 3.7 | – | – | – | 100 | 99 | |
| Marina (29) | 282 | 19/2+46/23 | 8 | – | – | – | 91 | ||
| Martinez-Monge (30) | 200 | 19/4+54/27 | 3.7 | 5 | 2 | – | 85 | ||
| Neviani (31) | 455 | 16.5–21/3+45/25 | 4 | 8 | 1 | 92 | 88 | 85 | |
| Olarte (32) | 183 | 19/4+54/27 | 8 | 8 | 2 | – | – | 89 | |
| 56 | 19/2+54/27 | 5 | 9 | 4 | – | – | 88 | ||
| Pellizzon (33) | 209 | 20/2+44/22 | 5.3 | – | 92 | 90 | 89 | ||
| Phan (34) | 309 | 15/3–26/4+36/18–50.4/28 | 4.9 | 4 | 0.3 | 98 | 90 | 78 | |
| Prada (35) | 313 | 23/2+46/23 | 5.7 | 2 | 0 | 100 | 88 | 79–91 | |
| Savdie (36) | 90 | 16.5/3+45/25 | 7.9 | 80 | |||||
| Vigneault (37) | 832 | 18/3–15/1+40/20–44/20 | 5.5 | 0.2 | 0 | 95 | 95 | 94 | |
| Whalley (38) | 101 | 17/2–19.5/3+46/23 | 4.7 | 2 | 0 | – | 95 | 66 | |
| Yaxley (39) | 507 | 16.5–19.5/3+46/23 | 10.3 | 14 | – | – | 93 | 74 | |
| Zwahlen (40) | 196 | 20/4–18/3+46/23 | 5.5 | 7 | 0 | – | 83 | – | |
FU, follow-up; HDR, high dose-rate.